Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland.

PubWeight™: 1.74‹?› | Rank: Top 3%

🔗 View Article (PMID 21514718)

Published in Eur Urol on April 16, 2011

Authors

Christopher J Weight1, Simon P Kim, Christine M Lohse, John C Cheville, R Houston Thompson, Stephen A Boorjian, Bradley C Leibovich

Author Affiliations

1: Department of Urology, Mayo Clinic, Rochester, MN 55905, USA.

Articles by these authors

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21

Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13

An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol (2002) 4.59

Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med (2002) 4.18

Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol (2004) 3.92

Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol (2010) 3.71

Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol (2003) 3.66

Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol (2007) 3.50

Solid renal tumors: an analysis of pathological features related to tumor size. J Urol (2003) 3.48

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (2003) 3.33

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23

USP10 regulates p53 localization and stability by deubiquitinating p53. Cell (2010) 3.17

The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol (2013) 3.11

Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer (2006) 3.08

Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06

Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. J Urol (2006) 3.05

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00

Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res (2003) 2.91

Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer (2014) 2.77

Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol (2012) 2.73

Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol (2004) 2.61

Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function. J Urol (2010) 2.53

Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol (2012) 2.52

Treatment of patients with small renal masses: a survey of the American Urological Association. J Urol (2010) 2.45

Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res (2005) 2.42

The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. Eur Urol (2008) 2.40

Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol (2010) 2.38

B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37

The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol (2007) 2.36

Small (<4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging. Radiology (2012) 2.35

Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol (2011) 2.33

B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24

Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol (2011) 2.22

Overall survival advantage with partial nephrectomy: a bias of observational data? Cancer (2013) 2.21

The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol (2013) 2.19

B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19

Temporal trends, practice patterns, and treatment outcomes for infected upper urinary tract stones in the United States. Eur Urol (2012) 2.16

Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care (2014) 2.14

Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int (2013) 2.12

Complications of contemporary open nephron sparing surgery: a single institution experience. J Urol (2005) 2.10

Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. Int J Urol (2014) 2.08

Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol (2004) 2.08

High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06

Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol (2009) 2.05

The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol (2013) 2.05

Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol (2005) 2.01

The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc (2012) 2.00

The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int (2004) 2.00

Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer (2009) 2.00

The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? J Urol (2013) 1.99